Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
HMPL-760 planned dose 1 Phase 2 Results Expected
HMPL-760 planned dose 1 • Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Target Indication
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clinical Trial
NCT06601504Last updated: 12/13/2025
Metastatic Pancreatic Cancer
Advanced Renal Cell Carcinoma
Acute Myeloid Leukemia
Advanced Endometrial Cancer
Relapsed/Refractory Lymphoma